{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:49:24Z","timestamp":1649105364649},"reference-count":151,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/mjt.0000000000000406","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T16:34:10Z","timestamp":1449851650000},"page":"e531-e549","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Heart Failure With Reduced Ejection Fraction\u2014Recent Developments"],"prefix":"10.1097","volume":"23","author":[{"given":"Andr\u00e9 Miguel Ramos","family":"Travessa","sequence":"first","affiliation":[]},{"given":"Luiz Filipe de","family":"Menezes Falc\u00e3o","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-25-20210202","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":". ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"R2-25-20210202","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure.","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"R3-25-20210202","first-page":"e29","article-title":". Heart disease and stroke statistics-2015 update: a report from the American Heart Association.","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"R5-25-20210202","first-page":"57","article-title":". Dilemmas in end-stage heart failure.","volume":"12","author":"Chen-Scarabelli","year":"2015","journal-title":"J Geriatr Cardiol"},{"key":"R7-25-20210202","first-page":"1","article-title":"Hospitalization for congestive heart failure: United States, 2000-2010.","volume":"108","author":"Hall","year":"2012","journal-title":"NCHS Data Brief"},{"key":"R8-25-20210202","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure.","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"R9-25-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2012.03.093","article-title":"A general theory of acute and chronic heart failure.","volume":"165","author":"MacIver","year":"2013","journal-title":"Int J Cardiol"},{"key":"R10-25-20210202","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.000045","article-title":". Natural history of left ventricular ejection fraction in patients with heart failure.","volume":"6","author":"Clarke","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R11-25-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12576-014-0314-y","article-title":". Cardiac thin filament regulation and the Frank-Starling mechanism.","volume":"64","author":"Kobirumaki-Shimozawa","year":"2014","journal-title":"J Physiol Sci"},{"key":"R12-25-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1755-5922.2009.00094.x","article-title":". Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure.","volume":"27","author":"Chaggar","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"R13-25-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","article-title":"The renin-angiotensin-aldosterone system and heart failure.","volume":"32","author":"Sayer","year":"2014","journal-title":"Cardiol Clin"},{"key":"R14-25-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MNH.0b013e3282f357da","article-title":"Renal hemodynamics in heart failure: implications for treatment.","volume":"17","author":"Rea","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R15-25-20210202","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","article-title":"Left ventricular remodelling after myocardial infarction: pathophysiology and therapy.","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"R17-25-20210202","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.110.979500","article-title":"Natriuretic peptide testing in heart failure.","volume":"123","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"R18-25-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/jmcc.1998.0842","article-title":"Secondary endothelial dysfunction: hypertension and heart failure.","volume":"31","author":"Boulanger","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"R19-25-20210202","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.CCM.0000297160.48694.90","article-title":". Cytokines and acute heart failure.","volume":"36","author":"Chen","year":"2008","journal-title":"Crit Care Med"},{"key":"R20-25-20210202","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5694\/mja12.10993","article-title":"Management of heart failure.","volume":"199","author":"Krum","year":"2013","journal-title":"Med J Aust"},{"key":"R21-25-20210202","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":". The natural history of congestive heart failure: the Framingham study.","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"R22-25-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-86-2-133","article-title":". Chronic congestive heart failure in coronary artery disease: clinical criteria.","volume":"86","author":"Harlan","year":"1977","journal-title":"Ann Intern Med"},{"key":"R23-25-20210202","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0021-9681(85)90115-8","article-title":". An analysis of physicians reasons for prescribing long-term digitalis therapy in outpatients.","volume":"38","author":"Carlson","year":"1985","journal-title":"J Chron Dis"},{"key":"R25-25-20210202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13547500903411087","article-title":". Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects.","volume":"15","author":"Martinez-Rumayor","year":"2010","journal-title":"Biomarkers"},{"key":"R26-25-20210202","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/hrt.2010.220426","article-title":". Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis.","volume":"97","author":"Kelder","year":"2011","journal-title":"Heart"},{"key":"R27-25-20210202","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":". 2013 ACCFAHA guideline for the management of heart failure: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines.","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R28-25-20210202","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1573403X09666131117123525","article-title":". Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence.","volume":"11","author":"Pruett","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"R29-25-20210202","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archinte.166.10.1081","article-title":". Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.","volume":"166","author":"Mueller","year":"2006","journal-title":"Arch Intern Med"},{"key":"R30-25-20210202","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.amjcard.2006.06.005","article-title":". Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department.","volume":"98","author":"Siebert","year":"2006","journal-title":"Am J Cardiol"},{"key":"R31-25-20210202","doi-asserted-by":"crossref","first-page":"h910","DOI":"10.1136\/bmj.h910","article-title":". The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting.","volume":"350","author":"Roberts","year":"2015","journal-title":"BMJ"},{"key":"R32-25-20210202","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/ajkd.2003.50118","article-title":". B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.","volume":"41","author":"McCullough","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R33-25-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":". Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.","volume":"176","author":"Madamanchi","year":"2014","journal-title":"Int J Cardiol"},{"key":"R34-25-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10741-014-9440-0","article-title":". A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.","volume":"19","author":"Oremus","year":"2014","journal-title":"Heart Fail Rev"},{"issue":"Suppl 4","key":"R36-25-20210202","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.2967\/jnumed.114.150433","article-title":"The role of echocardiography in heart failure.","volume":"56","author":"Marwick","year":"2015","journal-title":"J Nucl Med"},{"key":"R37-25-20210202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00108-013-3425-2","article-title":". Diagnostik der systolischen und diastolischen Herzinsuffizienz.","volume":"55","author":"Hummel","year":"2014","journal-title":"Der Internist"},{"key":"R38-25-20210202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/CIRCIMAGING.111.963496","article-title":". Echocardiographic evaluation of hemodynamics inpatients with decompensated systolic heart failure.","volume":"4","author":"Nagueh","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"R39-25-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":". Recommendations for chamber quantification.","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"R40-25-20210202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1573403X09666131117131217","article-title":"Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons.","volume":"11","author":"Oktay","year":"2015","journal-title":"Curr Cardiol Rev"},{"issue":"Suppl 1","key":"R41-25-20210202","first-page":"49","article-title":"Diastolic function in heart failure.","volume":"9","author":"Kovacs","year":"2015","journal-title":"Clin Med Insights Cardiol"},{"key":"R42-25-20210202","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cca.2014.08.016","article-title":". Troponins in heart failure.","volume":"443","author":"Omland","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R43-25-20210202","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cca.2014.12.027","article-title":"Cardiac troponin assays in the management of heart failure.","volume":"441C","author":"Torre","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R44-25-20210202","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2014.12.137","article-title":". Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis.","volume":"182","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"R45-25-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.repc.2014.10.005","article-title":"Galectina-3: indicador de prognostico.","volume":"34","author":"Pereira","year":"2015","journal-title":"Alvo de intervencao terapeutica Rev Port Cardiol"},{"key":"R46-25-20210202","first-page":"e004374","article-title":"Galectin-3 in heart failure: more answers or more questions J Am Heart Assoc.","volume":"1","author":"Ahmad","year":"2012","journal-title":""},{"key":"R47-25-20210202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cca.2014.09.021","article-title":"Soluble ST2 in heart failure.","volume":"30","author":"Dieplinger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R50-25-20210202","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.recesp.2015.02.009","article-title":"Biomarkers in acute heart failure.","volume":"68","author":"Mallick","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R51-25-20210202","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2014.10.023","article-title":"Multiple biomarker strategies for risk stratification in heart failure.","volume":"443","author":"Bayes-Genis","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R52-25-20210202","doi-asserted-by":"crossref","first-page":"e85466","DOI":"10.1371\/journal.pone.0085466","article-title":". Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator).","volume":"9","author":"Lupon","year":"2014","journal-title":"PLoS One"},{"key":"R53-25-20210202","first-page":"21","article-title":". Clinical scores in chronic heart failure: does an ideal score exist in Italian.","volume":"16","author":"Fontanive","year":"2015","journal-title":"G Ital Cardiol (Rome)"},{"key":"R54-25-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5339\/gcsp.2015.3","article-title":"Left ventricular diastolic function and dysfunction: Central role of echocardiography.","volume":"2015","author":"Dokainish","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"R55-25-20210202","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ehjci\/jev084","article-title":". EuroEcho-imaging 2014: highlights.","volume":"16","author":"Magne","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R56-25-20210202","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.echo.2013.07.009","article-title":". Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists.","volume":"26","author":"Hahn","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"R57-25-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2014.05.005","article-title":"Clinical application of three-dimensional echocardiography.","volume":"57","author":"Morbach","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"key":"R58-25-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-7120-10-27","article-title":". Real time 3D echocardiography (RT3D) for assessment of ventricular and vascular function in hypertensive and heart failure patients.","volume":"10","author":"Scali","year":"2012","journal-title":"Cardiovasc Ultrasound"},{"key":"R59-25-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1540-8175.2008.00865.x","article-title":"The role of speckle tracking strain imaging in cardiac pacing.","volume":"26","author":"Tops","year":"2009","journal-title":"Echocardiography"},{"key":"R60-25-20210202","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1253\/circj.CJ-14-0842","article-title":". The Speckle Tracking Imaging for the Assessment of Cardiac Resynchronization Therapy (START) study.","volume":"79","author":"Maruo","year":"2015","journal-title":"Circ J"},{"key":"R61-25-20210202","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cjca.2015.02.013","article-title":". Pharmacologic options for the management of systolic heart failure: examining underlying mechanisms.","volume":"31","author":"Mancini","year":"2015","journal-title":"Can J Cardiol"},{"key":"R62-25-20210202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":". The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R63-25-20210202","first-page":"CD003838","article-title":". Diuretics for heart failure.","volume":"2","author":"Faris","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R64-25-20210202","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2174\/1389450116666150531152047","article-title":". Updates on HCN channels in the heart: function, dysfunction and pharmacology.","volume":"16","author":"Sartiani","year":"2015","journal-title":"Curr Drug Targets"},{"key":"R65-25-20210202","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":". Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"R66-25-20210202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":". The global health and economic burden of hospitalizations for heart failure. Lessons learned from hospitalized heart failure registries.","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R67-25-20210202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":". Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R68-25-20210202","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":". Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"R69-25-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tetlet.2011.11.029","article-title":". LCZ696: a dual-acting sodium supramolecular complex.","volume":"53","author":"Feng","year":"2012","journal-title":"Tetrahedron Lett"},{"key":"R70-25-20210202","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov Today Ther Strateg"},{"key":"R71-25-20210202","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"; Paradigm-HF investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Eng J Med"},{"key":"R72-25-20210202","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":". Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"R73-25-20210202","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":". A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"R74-25-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":". Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"R75-25-20210202","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"; Prospective comparison of ARNI with ARB on Management of heart failure with preserved ejection fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R76-25-20210202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":". Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study.","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"R79-25-20210202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":". Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"R80-25-20210202","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":". Efficacy and safety of LCZ696, a first-in-class Angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"R82-25-20210202","first-page":"37","article-title":"LCZ696: the next step in improving RAS inhibition Curr Hypertens Rep.","volume":"17","author":"Gradman","year":"2015","journal-title":""},{"key":"R83-25-20210202","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":". Neprilysin inhibition in chronic kidney disease.","volume":"30","author":"Judge","year":"2015","journal-title":"Nephrol Dial Transpl"},{"key":"R84-25-20210202","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":". Cardiac resynchronization in chronic heart failure.","volume":"346","author":"Abraham","year":"2002","journal-title":"N Engl J Med"},{"key":"R85-25-20210202","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":". Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.","volume":"89","author":"Young","year":"2003","journal-title":"JAMA"},{"key":"R86-25-20210202","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(03)01042-8","article-title":". Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias.","volume":"42","author":"Higgins","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R87-25-20210202","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1161\/01.CIR.0000146336.92331.D1","article-title":". Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.","volume":"110","author":"Abraham","year":"2004","journal-title":"Circulation"},{"key":"R88-25-20210202","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":". Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"R89-25-20210202","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":". The effect of cardiac resynchronization on morbidity and mortality in heart failure.","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"R90-25-20210202","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa0706695","article-title":". Cardiac-resynchronization therapy in heart failure with narrow QRS complexes.","volume":"357","author":"Beshai","year":"2007","journal-title":"N Engl J Med"},{"key":"R91-25-20210202","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":". Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R92-25-20210202","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":". Cardiac-resynchronization therapy for the prevention of heart-failure events.","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"R93-25-20210202","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1401426","article-title":". Survival with cardiac-resynchronization therapy in mild heart failure.","volume":"370","author":"Goldenberg","year":"2014","journal-title":"N Engl J Med"},{"key":"R94-25-20210202","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":". Cardiac-resynchronization therapy for mild-to-moderate heart failure.","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"R95-25-20210202","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":". Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"R96-25-20210202","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HCO.0000000000000140","article-title":"Incidence, definition, diagnosis, and management of the cardiac resynchronization therapy nonresponder.","volume":"30","author":"Zhang","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"R97-25-20210202","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1536\/ihj.13-318","article-title":"Predictors for cardiac resynchronization therapy response: the importance of QRS morphology and left ventricular lead position.","volume":"55","author":"Lin","year":"2014","journal-title":"Int Heart J"},{"key":"R99-25-20210202","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/CIRCULATIONAHA.107.743120","article-title":". Results of the Predictors of Response to CRT (PROSPECT) trial.","volume":"117","author":"Chung","year":"2008","journal-title":"Circulation"},{"key":"R100-25-20210202","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.echo.2014.01.004","article-title":". Relationship between two-dimensional speckle-tracking septal strain and response to cardiac resynchronization therapy in patients with left ventricular dysfunction and left bundle branch block: a prospective pilot study.","volume":"27","author":"Marechaux","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"R101-25-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jcmg.2008.04.013","article-title":". Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy.","volume":"1","author":"Bilchick","year":"2008","journal-title":"JACC Cardiovasc Imaging"},{"key":"R102-25-20210202","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jelectrocard.2014.10.014","article-title":". Simplified Selvester Score: a practical electrocardiographic instrument to predict response to CRT.","volume":"48","author":"Bani","year":"2015","journal-title":"J Electrocardiol"},{"key":"R103-25-20210202","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/eurheartj\/ehp368","article-title":". Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis.","volume":"30","author":"van Bommel","year":"2009","journal-title":"Eur Heart J"},{"key":"R104-25-20210202","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.jacc.2012.01.065","article-title":". Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADITCRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) study.","volume":"59","author":"Hsu","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R105-25-20210202","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.hrthm.2010.04.005","article-title":". Characterization of super-response to cardiac resynchronization therapy.","volume":"7","author":"Rickard","year":"2010","journal-title":"Heart Rhythm"},{"key":"R106-25-20210202","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jelectrocard.2015.04.019","article-title":". Electrocardiographic parameters predict super-response in cardiac resynchronization therapy.","volume":"48","author":"Cvijic","year":"2015","journal-title":"J Electrocardiol"},{"key":"R107-25-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cardfail.2014.03.001","article-title":". Predictors and outcomes of super-response to cardiac resynchronization therapy.","volume":"20","author":"Killu","year":"2014","journal-title":"J Card Fail"},{"key":"R108-25-20210202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2008.06.043","article-title":". Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies.","volume":"52","author":"Upadhyay","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R109-25-20210202","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCULATIONAHA.110.960898","article-title":". Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT).","volume":"123","author":"Zareba","year":"2011","journal-title":"Circulation"},{"key":"R110-25-20210202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jelectrocard.2008.07.011","article-title":"The QRS complex--a biomarker that images the heart: QRS scores to quantify myocardial scar in the presence of normal and abnormal ventricular conduction.","volume":"42","author":"Strauss","year":"2009","journal-title":"J Electrocardiol"},{"key":"R111-25-20210202","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":". Biventricular pacing for atrioventricular block and systolic dysfunction.","volume":"368","author":"Curtis","year":"2013","journal-title":"N Engl J Med"},{"key":"R112-25-20210202","first-page":"384","article-title":"Cardiac resynchronization therapy defibrillator at the end of battery life: in an era of economic uncertainty, dosuper-responders provide an opportunity for resource optimization Int J Cardiol.","volume":"199","author":"Barra","year":"2015","journal-title":""},{"key":"R113-25-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18560","article-title":". Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.","volume":"18","author":"Colquitt","year":"2014","journal-title":"Health Technol Assess"},{"key":"R115-25-20210202","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/europace\/eur188","article-title":". Cost-effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.","volume":"13","author":"Maniadakis","year":"2011","journal-title":"Europace"},{"key":"R116-25-20210202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2011.06.046","article-title":". Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income countrys public health system.","volume":"163","author":"Bertoldi","year":"2013","journal-title":"Int J Cardiol"},{"key":"R117-25-20210202","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.12659\/MSM.893681","article-title":"Use of implantable cardioverter defibrillators in heart failure patients and risk of mortality: a meta-analysis.","volume":"21","author":"Zhang","year":"2015","journal-title":"Med Sci Monit"},{"key":"R118-25-20210202","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1161\/CIR.0b013e318276ce9b","article-title":". Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCFAHAHRS focused update incorporated into the ACCFAHAHRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.","volume":"127","author":"Epstein","year":"2013","journal-title":"Circulation"},{"key":"R119-25-20210202","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":". Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"R120-25-20210202","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":". Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators.","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"R121-25-20210202","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":". Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N Engl J Med"},{"key":"R122-25-20210202","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":". Defibrillator implantation early after myocardial infarction.","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N Engl J Med"},{"key":"R123-25-20210202","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":". Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies.","volume":"24","author":"Connolly","year":"2000","journal-title":"Eur Heart J"},{"key":"R124-25-20210202","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/CIRCOUTCOMES.114.001306","article-title":". Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter An analysis of pooled data from 5 clinical trials.","volume":"8","author":"Hess","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R125-25-20210202","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cjca.2014.11.023","article-title":". A Systematic review and meta-analysis of the association between implantable cardioverter-defibrillatorshocks and long-term mortality.","volume":"31","author":"Proietti","year":"2015","journal-title":"Can J Cardiol"},{"key":"R126-25-20210202","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00399-014-0307-9","article-title":"Electrical storm in ICD patients: prevention and treatment in German.","volume":"25","author":"Zarse","year":"2014","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"R127-25-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/pace.12238","article-title":". Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.","volume":"37","author":"Thijssen","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"R128-25-20210202","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2011.02.1180","article-title":"Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).","volume":"14","author":"Gandjour","year":"2011","journal-title":"Value Health"},{"key":"R129-25-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurheartj\/ehs090","article-title":". The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: an European analysis.","volume":"34","author":"Smith","year":"2013","journal-title":"Eur Heart J"},{"key":"R130-25-20210202","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10198-014-0637-x","article-title":". Economic evaluations of implantable cardioverter defibrillators: a systematic review.","volume":"16","author":"Garcia-Perez","year":"2015","journal-title":"Eur J Health Econ"},{"key":"R132-25-20210202","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/eurheartj\/ehu112","article-title":". EFFORTLESS study. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry.","volume":"35","author":"Lambiase","year":"2014","journal-title":"Eur Heart J"},{"key":"R134-25-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.healun.2014.04.010","article-title":". Sixth INTERMACS annual report: a 10,000-patient database.","volume":"33","author":"Kirklin","year":"2014","journal-title":"J Heart Lung Transpl"},{"key":"R135-25-20210202","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2015.04.039","article-title":"Left ventricular assist devices: a rapidly evolving alternative to transplant.","volume":"65","author":"Mancini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R136-25-20210202","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.jacc.2014.01.053","article-title":". Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support).","volume":"63","author":"Jorde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R137-25-20210202","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jtcvs.2013.09.012","article-title":"Implantable physiologic controller for left ventricular assist devices with telemetry capability.","volume":"147","author":"Asgari","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R138-25-20210202","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cardfail.2010.06.414","article-title":"NHLBIs program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial.","volume":"16","author":"Baldwin","year":"2010","journal-title":"J Card Fail"},{"key":"R139-25-20210202","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MAT.0b013e3180536694","article-title":". Design features, developmental status, and experimental results with the HeartMate III centrifugal left ventricular assist system with a magnetically levitated rotor.","volume":"53","author":"Farrar","year":"2007","journal-title":"ASAIO J"},{"key":"R140-25-20210202","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MAT.0000000000000038","article-title":". Early feasibility testing and engineering development of the transapical approach for the HeartWare MVAD ventricular assist system.","volume":"60","author":"Tamez","year":"2014","journal-title":"ASAIO J"},{"key":"R141-25-20210202","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/heartjnl-2014-306789","article-title":". Ventricular assist devices for treatment of acute heart failure and chronic heart failure.","volume":"101","author":"Kirkpatrick","year":"2015","journal-title":"Heart"},{"key":"R142-25-20210202","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000380915","article-title":". Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review.","volume":"5","author":"Lu","year":"2015","journal-title":"Cardiorenal Med"},{"key":"R143-25-20210202","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":". Ultrafiltration in decompensated heart failure with cardiorenal syndrome.","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"R144-25-20210202","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4330\/wjc.v7.i7.392","article-title":"Peritoneal dialysis for chronic cardiorenal syndrome: lessons learned from ultrafiltration trials.","volume":"7","author":"Kazory","year":"2015","journal-title":"World J Cardiol"},{"key":"R145-25-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/089686080902900314","article-title":"Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003.","volume":"29","author":"Davenport","year":"2009","journal-title":"Perit Dial Int"},{"key":"R146-25-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000341648","article-title":"Advances in peritoneal dialysis in acute kidney injury.","volume":"34","author":"Ponce","year":"2012","journal-title":"Blood Purif"},{"key":"R147-25-20210202","first-page":"365","article-title":". Adaptive practices in heart failure care teams: implications for patient-centered care in the context of complexity.","volume":"8","author":"Tait","year":"2015","journal-title":"J Multidiscip Healthc"},{"key":"R148-25-20210202","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1157\/13109002","article-title":"Heart failure units in Spain: state of the art in Spanish.","volume":"60","author":"Zamora","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"R149-25-20210202","first-page":"1","article-title":"Adherence to clinical guidelines in heart failure (HF) outpatients: impact of an interprofessional HF team onevidence-based medication use.","volume":"19","author":"Crissinger","year":"2015","journal-title":"J Interprof Care"},{"key":"R150-25-20210202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCHEARTFAILURE.112.971051","article-title":". A population-based study to evaluate the effectiveness of multidisciplinary heart failure clinics and identify important service components.","volume":"6","author":"Wijeysundera","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R151-25-20210202","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/CIRCHEARTFAILURE.113.001246","article-title":". Multidisciplinary group clinic appointments: the Self-Management and Care of Heart Failure (SMAC-HF) trial.","volume":"7","author":"Smith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R152-25-20210202","first-page":"810","article-title":". Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials.","volume":"44","author":"McAlister","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R153-25-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/M14-0083","article-title":". Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis.","volume":"160","author":"Feltner","year":"2014","journal-title":"Ann Intern Med"},{"key":"R154-25-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/01.CIR.0000080290.39027.48","article-title":". Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists.","volume":"108","author":"Jong","year":"2003","journal-title":"Circulation"},{"key":"R155-25-20210202","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMoa1010029","article-title":". Telemonitoring in patients with heart failure.","volume":"363","author":"Chaudhry","year":"2010","journal-title":"N Engl J Med"},{"key":"R156-25-20210202","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.2196\/jmir.4174","article-title":"Effects of home telemonitoring interventions on patients with chronic heart failure: an overview of systematic reviews.","volume":"17","author":"Kitsiou","year":"2015","journal-title":"J Med Internet Res"},{"key":"R157-25-20210202","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.clinthera.2015.08.012","article-title":"Current attitudes on cardiac devices in heart failure: a review.","volume":"37","author":"Marangou","year":"2015","journal-title":"Clin Ther"},{"key":"R158-25-20210202","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(14)61176-4","article-title":". Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial.","volume":"384","author":"Hindricks","year":"2014","journal-title":"Lancet"},{"key":"R159-25-20210202","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/europace\/euu318","article-title":". Remote monitoring improves outcome after ICD implantation: the clinical efficacy in the management of heart failure (EFFECT) study.","volume":"17","author":"De Simone","year":"2015","journal-title":"Europace"},{"key":"R160-25-20210202","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacc.2007.10.061","article-title":". Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.","volume":"51","author":"Bourge","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R161-25-20210202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.hfc.2014.12.011","article-title":"The role of implantable hemodynamic monitors to manage heart failure.","volume":"11","author":"Abraham","year":"2015","journal-title":"Heart Fail Clin"},{"key":"R163-25-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":". Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R165-25-20210202","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.111.043042","article-title":". Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure.","volume":"124","author":"van Veldhuisen","year":"2011","journal-title":"Circulation"},{"key":"R166-25-20210202","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/eurheartj\/ehr050","article-title":". Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial.","volume":"32","author":"Conraads","year":"2011","journal-title":"Eur Heart J"},{"key":"R167-25-20210202","first-page":"596","article-title":"Cardiac resynchronization therapy: history, present status, and future directions.","volume":"14","author":"Jaffe","year":"2014","journal-title":"Ochsner J"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000000406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:27:09Z","timestamp":1620962829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201603000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":151,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000000406","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}